|
Parameters
|
(-) (n = 43)
|
Cardiovascular event
| |
|---|
|
(+) (n = 38)
|
p value
|
|---|
|
Age
|
58 ± 17
|
66 ± 15
|
0.037
|
1)
|
|
Male
|
36
|
28
|
0.289
|
2)
|
|
NYHA functional class III-IV
|
6
|
12
|
0.067
|
2)
|
|
IHD
|
10
|
10
|
0.800
|
2)
|
|
Rhythm (Af / pacing)
|
10
|
17
|
0.059
|
2)
|
|
BNP (pg/mL)
|
580 ± 805
|
965 ± 903
|
0.005
|
3)
|
|
Total bilirubin (mg/dL)
|
0.93 ± 0.53
|
1.34 ± 0.98
|
0.018
|
1)
|
|
Uric acid (mg/dL)
|
7.08 ± 1.89
|
7.76 ± 3.18
|
0.235
|
1)
|
|
eGFR (mL/min/1.73 m2)
|
55.8 ± 18.9
|
44.9 ± 19.8
|
0.015
|
1)
|
|
Hemoglobin (g/dL)
|
14.3 ± 2.3
|
13.5 ± 1.9
|
0.081
|
1)
|
|
C-reactive protein (mg/dL)
|
1.4 ± 3.0
|
1.5 ± 2.9
|
0.039
|
3)
|
|
LAD (cm)
|
3.89 ± 0.66
|
4.43 ± 0.91
|
0.003
|
1)
|
|
IVSTd (cm)
|
1.08 ± 0.35
|
0.87 ± 0.24
|
0.004
|
1)
|
|
LVPWTd (cm)
|
1.11 ± 0.27
|
1.01 ± 0.21
|
0.070
|
1)
|
|
LVDd (cm)
|
6.06 ± 0.79
|
6.22 ± 1.25
|
0.465
|
1)
|
|
LVDs (cm)
|
5.28 ± 0.85
|
5.50 ± 1.28
|
0.356
|
1)
|
|
LVEF (%)
|
31.4 ± 7.6
|
28.5 ± 7.8
|
0.093
|
1)
|
|
RVOT-FS
|
0.38 ± 0.20
|
0.27 ± 0.17
|
0.008
|
1)
|
|
RVFAC (%)
|
38 ± 14
|
32 ± 14
|
0.086
|
1)
|
|
TR-PG (mmHg)
|
25 ± 14
|
25 ± 9
|
0.978
|
1)
|
|
Beta-blocker
|
25
|
29
|
0.102
|
2)
|
|
ACE-I/ARB
|
28
|
30
|
0.219
|
2)
|
|
Calcium channel blocker
|
11
|
6
|
0.413
|
2)
|
|
Diuretic
|
24
|
36
|
<0.0001
|
2)
|
|
Aldosterone antagonist
|
21
|
25
|
0.177
|
2)
|
- Values are expressed as absolute number or the mean ± SD. Each variable was analyzed by 1) unpaired t-test, 2) Fisher's exact test and 3) Mann-Whitney test.
-
NYHA New York Heart Association, IHD ischemic heart disease, Af atrial fibrillation, BNP brain natriuretic peptide, eGFR estimated glomerular filtration rate, LA left atrial dimension (diastole), IVSTd intraventricular septal wall thickness (diastole), LVPWTd left ventricular posterior wall thickness (diastole), LVDd left ventricular end-diastolic dimension, LVDs left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, RVFAC right ventricular fractional area change, TR-PG tricuspid regurgitation-pressure gradient, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II type 1 receptor antagonist.
